{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T21:08:22Z","timestamp":1777928902766,"version":"3.51.4"},"reference-count":42,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2016,9,10]],"date-time":"2016-09-10T00:00:00Z","timestamp":1473465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Med Screen"],"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To present the results of the first and second round human papilloma virus (HPV)-based screening programme in the Umbria region after three years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From August 2010 to November 2011, the entire female population aged 35\u201364 in a local health district was invited for HPV testing (HPV-DNA cobas4800 on a liquid-based cytology sample). HPV-negative women were re-invited after three years. For HPV-positive women, a slide was prepared and interpreted. Positive cytologies were referred to colposcopy; negatives were referred to repeat HPV after one year. If HPV was persistently positive, women were referred to colposcopy; if negative, to normal screening. Indicators of the first and second round are compared with those of cytology screening in the same area in the preceding three years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Participation was 56.5%, the same as cytology (56.6%). HPV-positivity was 6.4% (396\/6272), cytology triage positivity was 35.6%; 251 cytology negative women were referred to one-year HPV retesting, 84.1% complied, and 55.5% were positive. Total colposcopy referral was 4.1%, and for cytology 1%. The detection rate for cervical intraepithelial neoplasia grade 2 or more severe was 10\u2030, compared with 3.7\u2030 using cytology. After three years, HPV-positivity was 3.4% (129\/3831), overall colposcopy referral was 2.3% (most at one-year follow-up), and detection rate was 0.5\/1000.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The first round detection rate was more than twice that of cytology screening, while colposcopy referral increased fourfold. At the second round, the detection rate decreased dramatically, showing that longer interval and more conservative protocols are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0969141316663580","type":"journal-article","created":{"date-parts":[[2016,9,10]],"date-time":"2016-09-10T20:39:14Z","timestamp":1473539954000},"page":"153-162","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":21,"title":["Cervical human papilloma virus (HPV) DNA primary screening test: Results of a population-based screening programme in central Italy"],"prefix":"10.1177","volume":"24","author":[{"given":"Basilio","family":"Passamonti","sequence":"first","affiliation":[{"name":"Azienda USL Umbria 1 Perugia, Laboratorio Unico di Screening, Perugia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Gustinucci","sequence":"additional","affiliation":[{"name":"Azienda USL Umbria 1 Perugia, Laboratorio Unico di Screening, Perugia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Giorgi Rossi","sequence":"additional","affiliation":[{"name":"Servizio Interaziendale di Epidemiologia, AUSL Reggio Emilia, Italy"},{"name":"Arcispedale Santa Maria Nuova \u2013 IRCCS, Reggio Emilia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Cesarini","sequence":"additional","affiliation":[{"name":"Azienda USL Umbria 1 Perugia, Laboratorio Unico di Screening, Perugia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simonetta","family":"Bulletti","sequence":"additional","affiliation":[{"name":"Azienda USL Umbria 1 Perugia, Laboratorio Unico di Screening, Perugia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Carlani","sequence":"additional","affiliation":[{"name":"Azienda USL Umbria 1 Perugia, Laboratorio Unico di Screening, Perugia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Martinelli","sequence":"additional","affiliation":[{"name":"Azienda USL Umbria 1 Perugia, Laboratorio Unico di Screening, Perugia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Broccolini","sequence":"additional","affiliation":[{"name":"Azienda USL Umbria 1 Perugia, Laboratorio Unico di Screening, Perugia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"D\u2019Angelo","sequence":"additional","affiliation":[{"name":"Azienda USL Umbria 1 Perugia, Laboratorio Unico di Screening, Perugia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Rosaria","family":"D\u2019Amico","sequence":"additional","affiliation":[{"name":"Azienda USL Umbria 1 Perugia, Laboratorio Unico di Screening, Perugia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenio","family":"Di Dato","sequence":"additional","affiliation":[{"name":"Azienda USL Umbria 1 Perugia, Laboratorio Unico di Screening, Perugia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Galeazzi","sequence":"additional","affiliation":[{"name":"Azienda USL Umbria 1 Perugia, Laboratorio Unico di Screening, Perugia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morena","family":"Malaspina","sequence":"additional","affiliation":[{"name":"Azienda USL Umbria 1 Perugia, Laboratorio Unico di Screening, Perugia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoletta","family":"Spita","sequence":"additional","affiliation":[{"name":"Azienda USL Umbria 1 Perugia, Laboratorio Unico di Screening, Perugia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Tintori","sequence":"additional","affiliation":[{"name":"Azienda USL Umbria 1 Perugia, Laboratorio Unico di Screening, Perugia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Donata","family":"Giaimo","sequence":"additional","affiliation":[{"name":"Regione Umbria, Responsabile Servizio Prevenzione, Sanit\u00e0 Veterinaria e Sicurezza Alimentare"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2016,9,10]]},"reference":[{"key":"bibr1-0969141316663580","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61450-0"},{"key":"bibr2-0969141316663580","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70156-1"},{"key":"bibr3-0969141316663580","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa073204"},{"key":"bibr4-0969141316663580","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70360-2"},{"key":"bibr5-0969141316663580","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62218-7"},{"key":"bibr6-0969141316663580","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.06.095"},{"key":"bibr7-0969141316663580","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn065"},{"key":"bibr8-0969141316663580","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70731-8"},{"key":"bibr9-0969141316663580","volume-title":"Population screening for cervical cancer","author":"Health Council of the Netherlands","year":"2011"},{"issue":"5","key":"bibr10-0969141316663580","first-page":"e1","volume":"36","author":"Ronco G","year":"2012","journal-title":"Epidemiol Prev"},{"key":"bibr11-0969141316663580","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPTGD94EVRSJCG"},{"key":"bibr12-0969141316663580","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-156-12-201206190-00424"},{"key":"bibr13-0969141316663580","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.26056"},{"key":"bibr14-0969141316663580","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.4021"},{"key":"bibr15-0969141316663580","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.05.088"},{"key":"bibr16-0969141316663580","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.06.019"},{"key":"bibr17-0969141316663580","doi-asserted-by":"publisher","DOI":"10.1258\/jms.2010.009092"},{"key":"bibr18-0969141316663580","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj209"},{"key":"bibr19-0969141316663580","doi-asserted-by":"publisher","DOI":"10.3310\/hta13510"},{"key":"bibr20-0969141316663580","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa071430"},{"key":"bibr21-0969141316663580","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70188-7"},{"key":"bibr22-0969141316663580","author":"Bergeron C","journal-title":"JNCI"},{"key":"bibr23-0969141316663580","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.12272"},{"key":"bibr24-0969141316663580","doi-asserted-by":"publisher","DOI":"10.1177\/0969141314561707"},{"key":"bibr25-0969141316663580","doi-asserted-by":"publisher","DOI":"10.1177\/0969141314522219"},{"key":"bibr26-0969141316663580","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28783"},{"key":"bibr27-0969141316663580","unstructured":"Gruppo Italiano Screening Citologico (GISCi). Raccomandazioni sul test HR-HPV come test di screening primario e rivisitazione del ruolo del Pap test, Belluno: Evidenzia, 2010, pp.  pp. 19\u2013 pp. 19.  (Italian)."},{"key":"bibr28-0969141316663580","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqv019"},{"key":"bibr29-0969141316663580","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.16.2114"},{"key":"bibr30-0969141316663580","unstructured":"Gruppo di lavoro GISCi approfondimenti diagnostici e trattamento manuale. Manuale del II livello. Raccomandazioni per la qualit\u00e0 nella diagnosi, terapia e follow up delle lesioni cervicali, nell\u2019ambito dei programmi di screening II livello, www.gisci.it\/documenti\/documenti_gisci\/Manuale_del_II_Livello.pdf (accessed 24 July 2014)."},{"key":"bibr31-0969141316663580","volume-title":"European Commission. European Guidelines for quality assurance in cervical cancer screening","author":"Arbyn M","year":"2008","edition":"2"},{"key":"bibr32-0969141316663580","first-page":"77","volume":"39","author":"Ronco G","year":"2015","journal-title":"Epidemiol Prev"},{"key":"bibr33-0969141316663580","doi-asserted-by":"crossref","unstructured":"Campari C, Fedato C, Iossa A, et\u00a0al; the GISCi Migrant Working Group. Cervical cancer screening in immigrant women in Italy: a survey on participation, cytology, and histology results.\n                      Eur J Cancer Prev\n                      2016; 25: 321\u2013328.","DOI":"10.1097\/CEJ.0000000000000173"},{"key":"bibr34-0969141316663580","first-page":"88","volume":"36","author":"Magnani C","year":"2012","journal-title":"Epidemiol Prev"},{"key":"bibr35-0969141316663580","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2008.07.021"},{"key":"bibr36-0969141316663580","unstructured":"Gruppo Italiano Screening Citologico (GISCi). La\n                      citologia di triage nei programmi di screening con HPV come test primario\n                      , Belluno: Evidenzia, 2013, pp.  pp. 16\u2013 pp. 16.  (Italian)."},{"key":"bibr37-0969141316663580","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2007.07.049"},{"key":"bibr38-0969141316663580","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwg171"},{"key":"bibr39-0969141316663580","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605771"},{"key":"bibr40-0969141316663580","unstructured":"Anttila A, Arbyn M, de Vuyst H, et\u00a0al. (eds)\n                      European Commission European guidelines for quality assurance in cervical cancer screening\n                      . 2nd ed. Supplements. Luxembourg: Office for Official Publications of the European Communities, 2015."},{"key":"bibr41-0969141316663580","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djq001"},{"key":"bibr42-0969141316663580","first-page":"61","volume":"39","author":"Ronco G","year":"2015","journal-title":"Epidemiol Prev"}],"container-title":["Journal of Medical Screening"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0969141316663580","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0969141316663580","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0969141316663580","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:23:57Z","timestamp":1777677837000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0969141316663580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,10]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["10.1177\/0969141316663580"],"URL":"https:\/\/doi.org\/10.1177\/0969141316663580","relation":{},"ISSN":["0969-1413","1475-5793"],"issn-type":[{"value":"0969-1413","type":"print"},{"value":"1475-5793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,10]]}}}